advanced search
Aptar Pharma

NASAL

NASAL
PATIENT SAFETY: KEY DRIVER TO PRESERVATIVE-FREE NASAL SPRAY DEVELOPMENT
Benoît Guillard, Pascale Farjas  and Audrey Chandra look at the effects of preservatives in nasal sprays, and the challenges and advantages of delivering preservative-free nasal spray drugs.
NASAL
WHEN EVERY SECOND COUNTS…
Todd Pizitz and Donald Mealing look at efforts to reduce the number of opioid-related deaths in the United States, and introduce a nasal device that delivers naloxone.
THE CURRENT STATE OF PLAY IN CONNECTED DEVICES
CONNECTIVITY
Marcus Bates
Aptar Pharma
THE CURRENT STATE OF PLAY IN CONNECTED DEVICES
Marcus Bates; Joachim Koerner and Jerôme Prraquin discuss the current state of play, what connected device advocates are doing to enable faster implementation, and how we can optimise connected technology while reducing the cost and improving human factors.
A FASTER, MORE COST-EFFECTIVE ALTERNATIVE TO GENERIC BIOEQUIVALENCE
RESPIRATORY
Dr Jag Shur
Nanopharm
A FASTER, MORE COST-EFFECTIVE ALTERNATIVE TO GENERIC BIOEQUIVALENCE
Jag Shur explores the challenges companies face in bringing generic respiratory and nasal therapies to market – and how some organisations have proactively addressed the challenge and developed services to integrate the device and the formulation, introducing the Aptar Pharma Services offering.
F2V: A STERILE, CUSTOMISABLE LIQUID FILL-FINISH PLATFORM FOR THE TOTAL LIFECYCLE
INDUSTRIALISATION
Simon Strothers
3P Innovation
F2V: A STERILE, CUSTOMISABLE LIQUID FILL-FINISH PLATFORM FOR THE TOTAL LIFECYCLE
Simon Strothers presents an integrated fill-finish platform, F2V, designed to represent a commercial filling system as a bench-top solution. The article also includes a recent case study where the F2V was used by Consort Medical to help develop and industrialise a flagship delivery device. 
CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL
CONNECTIVITY
Thierry Decock
Nemera
CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL
Thierry Decock and Hadrien Gremillet explore how the obstacles to the adoption of connectivity can be overcome and how connected devices can deliver truly patient-centric care that will clearly improve adherence rates, whilst demonstrating a clear cost benefit to the pharmaceutical partner.
BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE
RESPIRATORY
Joe Reynolds
Noble
BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE
Joe Reynolds discusses the current state of pulmonary drug delivery device trainers, including their value to patients, the complexities of modern design and the stringent quality requirements.
GUILLAUME BROUET, APTAR PHARMA
INTERVIEW
Guillaume Brouet
Aptar Pharma
GUILLAUME BROUET, APTAR PHARMA
Guillaume Brouet talks with ONdrugDelivery Magazine about how Aptar Pharma uses its device development expertise and infrastructure to provide its pharmaceutical company customers a comprehensive services offering around device development, global regulatory approval and commercialisation.
THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT
EXPERT VIEW
David Belton
THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT
David Belton discusses the meaning of quality by design in novel respiratory drug delivery device development. He covers how, with more novel devices, prior knowledge may be insufficient for a standard FMEA-style risk analysis, and alternate science-based methods, such as functional mapping and knowledge scoring, can help in achieving QbD.
PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP
INTERVIEW
Paul Allsop
Consort Medical
PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP
Consort Medical's Paul Allsop, Miles Kottman, Hannah Priestly and Jon Reed talk with ONdrugDelivery Magazine about the company’s integrated formulation and device offering, and focus on its simple, low-cost, single unit-dose, spring powered nasal device, Unidose Xtra.
130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC
NASAL
Dr Todd Pizitz
CounterAct
130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC
Todd Pizitz and Donald Mealing discuss the ongoing opioid crisis in the US and the current use of the opioid reversal medication naxalone, and introduce the CounterAct device for naxalone home use.
IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?
EXPERT VIEW
Dr Igor Gonda
IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?
Igor Gonda covers the field of nasal and pulmonary delivery of biologics, considers past failures and successes, and proposes answers to the challenges faced, from biological, biopharmaceutical and commercial standpoints.
BK814 The Unidose™ Xtra nasal spray device: designed for simplicity
VIDEO
Consort Medical
BK814 The Unidose™ Xtra nasal spray device: designed for simplicity
In this Video Consort Medical's Bespak division introduces its single dose Unidose™ Xtra nasal spray device offers unique performance advantages through the use of IP-protected mechanisms that control device actuation and aqueous drug delivery.
REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION
RESPIRATORY
Heli Chauhan
Proveris Scientific
REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION
Heli Chauhan and Linda (Lingzhi) Liao discuss the importance of automated actuation for testing inhalation and spray devices to avoid variability introduced by manual method.
NASAL DRUG DELIVERY VIA THE ORAL ROUTE USING A PMDI
NASAL
Dr Laurent Vecellio
University of Tours
NASAL DRUG DELIVERY VIA THE ORAL ROUTE USING A PMDI
Laurent Vecellio, Déborah Le Pennec and Alain Regard, Technology Product Manage discuss a study Nemera has funded into the retronose concept, using a pMDI to deliver to the nasal cavity via the oral route during exhalation through the nose.
EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY
CONNECTIVITY
Nemera
EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY
Nemera introduces the e-Novelia® and e-Advancia® add-ons for ophthalmic and nasal devices.
DRUG REPURPOSING – BROADENING PATIENT ACCESSIBILITY VIA A CHANGE IN DRUG DELIVERY SYSTEM
NASAL
Badre Hammond
Aptar Pharma
DRUG REPURPOSING – BROADENING PATIENT ACCESSIBILITY VIA A CHANGE IN DRUG DELIVERY SYSTEM
Badre Hammond, Gerallt Williams and Herve Pacaud discuss the growing trend of drug repurposing.
INFLUENCE OF THE HUMAN FACTOR ON NASAL DRUG DELIVERY DEVICE EVALUATION
NASAL
Pascale Farjas
Nemera
INFLUENCE OF THE HUMAN FACTOR ON NASAL DRUG DELIVERY DEVICE EVALUATION
Pascale Farjas, Alain Regard and Guillaume Grevin, discuss what is required of a modern nasal spray pump and how introducing the human factor showed a significant impact on the variability of delivered volume.
ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE
NASAL
Heli Chauhan
Proveris Scientific
ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE
Heli Chauhan details the myriad challenges facing the OINDP market, with a particular emphasis on nasal spray devices, when it comes to testing products on a mass-production scale, such as a lack of adequate testing equipment and the need to capture accurate data consistently. She goes on to offer a solution in the form of Indizo®, Proveris’ automated nasal spray testing apparatus.
THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY
NASAL
Pascale Farjas
Nemera
THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY
Pascale Farjas, Alain Regard, and Céline Petitcolas discuss the steps taken when designing a nasal spray device for the growing bioequivalence market and the key competencies, including experience with regulations and regulatory agencies in numerous geographic regions, that Nemera can offer throughout the process.
INNOVATIVE NASAL APPLICATION REQUIRES INNOVATIVE FILLING TECHNOLOGY
EXPERT VIEW
Dr Karlheinz Seyfang
INNOVATIVE NASAL APPLICATION REQUIRES INNOVATIVE FILLING TECHNOLOGY
Karlheinz Seyfang discusses the development of a system for the nasal delivery of a thixotropic gel formulation, from the design of the system through to the production line.
CONTROLLED-RELEASE SYSTEMS FOR PROTEINS & PEPTIDES
EXPERT VIEW
Dr S Mohan Mohanraj
CONTROLLED-RELEASE SYSTEMS FOR PROTEINS & PEPTIDES
S Mohan Mohanraj and Meier Kende discuss development of a viable intranasal microsphere-based delivery system and how it delivers a recombinant anthrax vaccine via two-dose immunisation.
A TRUE PLATFORM OFFERING EFFICIENT NASAL DOSE DELIVERY
NASAL
Pascale Farjas
Nemera
A TRUE PLATFORM OFFERING EFFICIENT NASAL DOSE DELIVERY
Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. Pascale Farjas, provides an overview of an innovative nasal delivery system, Advancia®, a true platform.
BIOEQUIVALENCE FOR NASAL SPRAYS: IMPORTANCE OF DEVICE PERFORMANCE
NASAL
Pascale Farjas
Nemera
BIOEQUIVALENCE FOR NASAL SPRAYS: IMPORTANCE OF DEVICE PERFORMANCE
Pascale Farjas describes the company’s Device Equivalence Program, which enables Nemera to preselect and propose an appropriate delivery system per identified drug to companies wishing to save time in their nasal spray development pipeline.
SONIC NEBULISATION IN RHINOLOGY
NASAL
Dr Laurent Vecellio
AeroDrug
SONIC NEBULISATION IN RHINOLOGY
Laurent Vecellio, Sandrine Le Guellec and Gilles Chantrel describe a sonic nasal nebuliser that operates with an acoustic frequency of 100Hz, and clinical studies demonstrating its efficacy in the delivery of treatments for CRS.
SCOPING THE DESIGN SPACE FOR GENERIC NASAL SPRAYS
NASAL
Dr Deborah Huck-Jones
Malvern Panalytical
SCOPING THE DESIGN SPACE FOR GENERIC NASAL SPRAYS
Deborah Huck-Jones and Paul Kippax discuss analytical methods that can be helpful for demonstrating bioequivalence in the development of generic nasal sprays.
Top

W3 Total Cache is currently running in Pro version Development mode.